Natural Capsules Ltd
Natural Capsules Q1 FY27: Revenue ₹48.71 Cr, PAT ₹5.74 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Natural Capsules Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q1FY27: ₹48.71 crore - Year-on-year (Y-o-Y) revenue growth: +8% - Sales volumes are not explicitly quantified in numbers but Q1FY27 delivery of capsule products had sustained demand per management commentary. Quarterly EBITDA: ₹1.12 crore, up 251% year-on-year (YoY), down 16% quarter-on-quarter (QoQ) - EBITDA Margin: 2.30%, up 159 basis points YoY, up 2 basis points QoQ - Profit After Tax (PAT): Loss of ₹5.74 crore, a 3% improvement YoY, 15% worse QoQ - Revenue from Operations: ₹48.71 crore, up 8% YoY, down 17% QoQ Margin Outlook (Management Commentary): - Capsules business delivered healthy margins with successful cost pass-throughs supporting margin preservation.
From Natural Capsules Ltd's Q1 FY27 earnings-call transcript · updated 1 Oct 2026.
Revenue & Sales Performance
- Revenue from Operations for Q1FY27: ₹48.71 crore
- Year-on-year (Y-o-Y) revenue growth: +8%
- Sales volumes are not explicitly quantified in numbers but Q1FY27 delivery of capsule products had sustained demand per management commentary.
- EBITDA for Q1FY27: ₹1.12 crore, up 251% Y-o-Y
- Management outlook: Confident of sustained performance and profitably in the capsules business through the financial year and sustained demand trends into Q2FY27.
- Temporary conversion of HPMC lines to gelatin lines to optimize capacity and protect profitability due to erratic US market demand.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Natural Capsules Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Installed capsules manufacturing capacity as at FY26 stands at 20.25 billion capsules per annum (BCPA), increased from 19.50 BCPA by commissioning one new HPMC line machine in FY26 (Page 12, 18).
- Plans to explore setting up capsules manufacturing facilities in foreign/domestic markets to ensure quick supply (Page 27).
- Investment in technology and manufacturing processes to attain efficiencies and competitive advantage noted (Page 28).
- API facility approvals received; commercial sales initiated in Q4FY26; scaling up production ongoing targeting regulated markets with stronger profitability (Page 28).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Natural Capsules Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Natural Capsules Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹58 Cr, net loss ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natural Capsules Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Natural Capsules Ltd Q1 FY27 results?
Revenue from Operations for Q1FY27: ₹48.71 crore - Year-on-year (Y-o-Y) revenue growth: +8% - Sales volumes are not explicitly quantified in numbers but Q1FY27 delivery of capsule products had sustained demand per management commentary. Quarterly EBITDA: ₹1.12 crore, up 251% year-on-year (YoY), down 16% quarter-on-quarter (QoQ) - EBITDA Margin: 2.30%, up 159 basis points YoY, up 2 basis points QoQ - Profit After Tax (PAT): Loss of ₹5.74 crore, a 3% improvement YoY, 15% worse QoQ - Revenue from Operations: ₹48.71 crore, up 8% YoY, down 17% QoQ Margin Outlook (Management Commentary): - Capsules business delivered healthy margins with successful cost pass-throughs supporting margin preservation.
What is Natural Capsules Ltd share price analysis?
Natural Capsules Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹197 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules Ltd planning capital expenditure?
Installed capsules manufacturing capacity as at FY26 stands at 20.25 billion capsules per annum (BCPA), increased from 19.50 BCPA by commissioning one new HPMC line machine in FY26 (Page 12, 18).
Keep Natural Capsules Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.